All In Biotech

Free tool

FAERS Monitor: Ubrelvy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211765 or its brand name (Ubrelvy, Ubrogepant). Reports on generic versions are filed under their own applications.

Reports

6,366

Serious

2,277

36% of reports

Hospitalization

693

Death reported

107

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,069
  • migraine921
  • headache575
  • nausea553
  • fatigue389
  • off label use300
  • dizziness282
  • pain280
  • product dose omission issue240
  • vomiting226
  • pruritus188
  • diarrhoea178
  • injection site pain174
  • somnolence166
  • feeling abnormal159

Reports by year received

View as table
YearReports
20151
20169
20171
20184
201917
2020449
2021643
20221,125
2023947
20241,053
20251,096
20261,021

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,793 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
migraineSignal92132.230.327,648
headacheSignal5753.02.8804
somnolenceSignal1662.72.3181
product dose omission issueSignal2402.72.4258
drug ineffectiveSignal1,0692.72.51,200
nauseaSignal5532.32.1425
feeling abnormalSignal1592.21.9103
injection site pain1741.91.671
dizziness2821.91.7116
fatigue3891.71.5103
pruritus1881.61.444
vomiting2261.61.450
pain2801.51.349
off label use3001.11.05
diarrhoea1780.90.82

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.